Karen Afenjar
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Cancer Research top 10%
- Radiology, Nuclear Medicine and Imaging top 10%
- Surgery
- Co-authors
- Dennis J. SlamonYvonne G. LinW. Fraser SymmansHans‐Joachim HelmsDaniil StroyakovskiySara A. HurvitzVicente ValeroJoseph A. Sparano
- Topics
- Cancer Treatment and Pharmacology (6 papers)Lung Cancer Treatments and Mutations (6 papers)Colorectal Cancer Treatments and Studies (5 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Karen Afenjar
15 papers receiving 564 citations
Hit Papers
Peers
Comparison fields: 5 of 47
- Oncology 461
- Pulmonary and Respiratory Medicine 218
- Cancer Research 193
- Radiology, Nuclear Medicine and Imaging 168
- Surgery 56
Countries citing papers authored by Karen Afenjar
This map shows the geographic impact of Karen Afenjar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Afenjar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Afenjar more than expected).
Fields of papers citing papers by Karen Afenjar
This network shows the impact of papers produced by Karen Afenjar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Afenjar. The network helps show where Karen Afenjar may publish in the future.
Co-authorship network of co-authors of Karen Afenjar
This figure shows the co-authorship network connecting the top 25 collaborators of Karen Afenjar. A scholar is included among the top collaborators of Karen Afenjar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Afenjar. Karen Afenjar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 2 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | 4 | |
| 6 | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialbreakdown → | 337 |
| 7 | 75 | |
| 8 | 33 | |
| 9 | 1 | |
| 10 | 2 | |
| 11 | 97 | |
| 12 | 5 | |
| 13 | 6 | |
| 14 | 1 | |
| 15 | 4 |
About Karen Afenjar
Karen Afenjar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 15 papers that have together received 571 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). The work is most often cited by research in Oncology (461 citations), Cancer Research (193 citations) and Gastroenterology (47 citations). Karen Afenjar has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Dennis J. Slamon, Yvonne G. Lin, W. Fraser Symmans, Hans‐Joachim Helms, Daniil Stroyakovskiy, Sara A. Hurvitz, Vicente Valero, Joseph A. Sparano, Alastair M. Thompson and Nadia Harbeck. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.